Nephroprotection in Severe Trauma Patients With Kidney Stress
Condition(s) studied
Investigational drug(s) / intervention(s)
Standard-of-care: Management according to current ICU practices
Systematic nephroprotection bundle-of-care: The nephroprotection bundle-of-care includes 5 components: 1. Prevention of drugs' nephrotoxicity 2. Hemodynamic optimization, for 24h 3. Blood glucose control and avoidance of hyperglycemia 4. Early detection of rhabdomyolysis 5. Monitoring of renal function
Study summary
Acute Kidney Injury (AKI) occurs in 24% of trauma patients, and is even more common in those with severe trauma. It is a major contributor to morbidity and mortality in trauma. Diagnosis of AKI is based on elevated serum creatinine and decreased urine output, two functional markers already indicating the presence of a significant kidney function impairment. Earlier detection of kidney stress, at a preclinical stage when cellular modifications are still reversible, could reduce the occurrence of AKI episodes if nephroprotective measures are rapidly implemented.
Several randomized controlled trials have shown that early implementation of such a nephroprotection bundle-of-care in patients at risk of AKI after major surgery reduces the incidence of severe AKI within 72 hours. Although its use is supported by international guidelines, this nephroprotection bundle-of-care is rarely implemented in its totality, due to the significant financial and human resources required for its full implementation.
The Nephrocheck® (NC) test is a urine test for which a result \> 0.3 is predictive of AKI development. It might enable early identification of trauma patients at risk of AKI, so that implementation of the nephroprotection bundle-of-care could be targeted solely at those high-risk patients.
Thus, the investigators hypothesize that in a population of severe trauma patients (ISS score\>15) at risk of AKI (defined by a NC on Intensive Care Unit (ICU) admission \> 0.3), early implementation of a nephroprotection bundle-of-care would reduce the risk of AKI occurring within 3 days of ICU admission, compared with standard-of-care management. This study will compare the occurrence of AKI in these two groups in a multicenter randomized controlled trial.
Eligibility
Primary outcome measure(s)
- Proportion of patients developing an AKI episode within 3 days after ICU admission. — During 3 days from ICU admission.
AKI will be defined according to KDIGO (Kidney Disease: Improving Global Outcomes) criteria, either by a drop in urine output (oliguria \< 0.5ml/kg/h for 6h) and/or a rise in serum creatinine (1.5x baseline or increase of 26.5 µmol/l).
Trial sites (6)
| Facility | City | Region | Status |
|---|---|---|---|
| Centre Hospitalier universitaire Estaing, Service anesthésie-réanimation | Clermont-Ferrand | France | Recruiting |
| Centre hospitaler Annecy Genevois, Service de réanimation | Épagny | France | Recruiting |
| Centre hospitalier universitaire de Grenoble Alpes, Pôle anesthésie-réanimation | La Tronche | France | Recruiting |
| Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'anesthésie-réanimation | Lyon | France | Recruiting |
| Hospices Civils de Lyon, Hôpital Lyon-Sud, Service d'anesthésie-réanimation | Pierre-Bénite | France | Recruiting |
| Centre hospitalier universitaire de Saint Etienne, Hôpital Bellevue, Service anesthésie-réanimation | Saint-Etienne | France | Recruiting |
More Hospices Civils de Lyon trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06834633 on ClinicalTrials.gov ↗ ← All trials in France